About Sarah Cannon Research Institute Drug Development Unit
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Sarah Cannon Research Institute Drug Development Unit
During the past decade, Sarah Cannon Research Institute Drug Development Unit conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 6 clinical trials were completed, i.e. on
average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
2009-03-25
2012-10-18
Terminated
105
Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects
2010-08-01
2013-10-01
Completed
800
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
2011-02-01
2014-02-01
Completed
799
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
2012-10-24
2018-09-06
Completed
583
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
2013-03-12
2018-10-03
Completed
872
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Sarah Cannon Research Institute Drug Development Unit"
#1 collaborator was "Agios Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at Sarah Cannon Research Institute Drug Development Unit
According to Clinical.Site data, the most researched conditions in "Sarah Cannon Research Institute Drug Development Unit" are
"Carcinoma, Non-Small-Cell Lung" (3 trials), "Multiple Myeloma" (3 trials), "Non-Small Cell Lung Cancer" (3 trials), "Colorectal Cancer" (2 trials) and "Glioblastoma Multiforme" (2 trials). Many other conditions were trialed in "Sarah Cannon Research Institute Drug Development Unit" in a lesser frequency.
Clinical Trials Intervention Types at Sarah Cannon Research Institute Drug Development Unit
Most popular intervention types in "Sarah Cannon Research Institute Drug Development Unit" are "Drug" (16 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Binimetinib" (2 trials), "LDK378" (2 trials), "ACY-1215" (1 trials), "Axitinib" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Sarah Cannon Research Institute Drug Development Unit
The vast majority of trials in "Sarah Cannon Research Institute Drug Development Unit" are
16 trials for "All" genders.
Clinical Trials Status at Sarah Cannon Research Institute Drug Development Unit
Currently, there are NaN active trials in "Sarah Cannon Research Institute Drug Development Unit".
undefined are not yet recruiting,
2 are recruiting,
6 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 6 completed trials in Sarah Cannon Research Institute Drug Development Unit,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Sarah Cannon Research Institute Drug Development Unit, 11 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".